Simultaneous determination of lipoic acid (LA) and dihydrolipoic acid (DHLA) in human plasma using high-performance liquid chromatography coupled with electrochemical detection

Polymeric nanocomposite electrode for enhanced electrochemical detection of α-lipoic acid: Application in neuroinflammation prevention and clinical analysis

Using poly (vanillin-co-chitosan)/functionalized MWCNTs/GCE (PV-CS/f-MWCNTs/GCE) as a polymeric nanocomposite modified electrode, the present investigation has been conducted on the electrochemical detection of α-lipoic acid (α-LA) to prevent the activation of microglia inflammation of the nervous system. The manufacture of modified polymeric nanocomposite electrodes was carried out using the established electropolymerization process. Field emission scanning electron microscopy (FE-SEM) and X-ray diffraction (XRD) analyses of structure revealed that the electropolymerization of poly (vanillin-co-chitosan) on the surface of the f-MWCNTs modified electrode was successful. Vanillin-co-chitosan electropolymerization on f-MWCNTs as electroactive sheets can enhance the signal for α-LA electrochemical sensors, according to research on the electrochemical characteristics utilizing cyclic voltammetry (CV) and differential pulse voltammetry (DPV) methodologies. The PV-CS/f-MWCNTs/GCE demonstrated that it had a sensitivity of 0.04664 μA/μM, a detection limit of 0.012 μM, and an excellent response, linear range, and wide linear range to α-LA from 0 to 3000 μM. The results of the application of PV-CS/f-MWCNTs/GCE for determining the concentration of α-LA in a prepared real sample of human serum by DPV and human lipoic acid ELISA Kit analyses via standard addition method illustrated the substantial conformity between the findings of both assays. The results of the DPV analyses resulted in acceptable recovery values (97.60%-99.10%) and appropriate values of the Relative Standard Deviation (RSD) (3.58%-5.07%), which demonstrated the great applicability and accuracy of the results of PV-CS/f-MWCNTs/GCE for determining α-LA concentration in biological fluids and pharmaceutical specimens.

Bioanalytical methods for the detection of duloxetine and thioctic acid in plasma using ultra performance liquid chromatography with tandem mass spectrometry (UPLC-MS/MS)

Duloxetine and thioctic acid (TA) are standard drugs for treating diabetic neuropathy, a primary complication associated with diabetes. In this study, ultra performance liquid chromatography coupled with tandem mass spectrometry methods was successfully developed and validated for quantifying duloxetine and TA in biological samples. The protein precipitation method was used to extract duloxetine, TA and their internal standards from beagle dog plasma. A Hypersil Gold C18 column (150 × 2.1 mm, 1.9 μm) was used for the experiment. Isocratic elution with 0.1% formic acid in acetonitrile (A) and 0.1% formic acid (B) was used for duloxetine, whereas a gradient elution with 0.03% acetic acid (A) and acetonitrile (B) was used for TA. The validated parameters included linearity, sensitivity, accuracy, precision, selectivity, matrix effect, stability, and recovery under different conditions. The linear ranges of the calibration curves for duloxetine and TA were 5–800 ng/mL and 5–1,000 ng/mL, respectively. An intra- and inter-run precision of ± 15% can be observed in all quality control samples. These methods were successfully used for pharmacokinetics (PKs) studies in beagle dogs to compare PK differences in a fixed-dose combination including duloxetine and TA and co-administration of the 2 drugs.

Scientific opinion on the relationship between intake of alpha-lipoic acid (thioctic acid) and the risk of insulin autoimmune syndrome

Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on the relationship between alpha-lipoic acid (ALA) and the risk of insulin autoimmune syndrome (IAS). The Panel was also asked to advise on the dose below which ALA added to foods is not expected to cause IAS. A review of all possible adverse effects associated with consumption of ALA was not requested. This mandate refers to the procedure under Article 8(2) of Regulation (EC) No 1925/2006 on addition of vitamins, minerals and certain other substances to foods. No pre-established rule exists for the evaluation of the safety of foods when classical toxicity tests cannot be used, e.g. for autoimmune diseases. Published scientific evidence was retrieved through comprehensive literature searches, particularly 49 case reports in which IAS developed following ALA consumption. In all cases, IAS resolved after a few weeks to months when ALA was discontinued. No publication linking the intake of ALA naturally occurring in foods to IAS was identified. The Panel concludes that the consumption of ALA added to foods, including food supplements, is likely to increase the risk of developing IAS in individuals with certain genetic polymorphisms, who cannot be readily identified without genetic testing. The plausible mechanism of such an effect has not yet been fully elucidated. The incidence of IAS in Europe is low and likely lower than in Japan where it has been estimated to be 0.017 per 100,000 inhabitants in 2017-2018. Considering the limited data available, the risk associated with the development of IAS following ALA consumption cannot be quantified precisely. An ALA dose below which IAS is not expected to occur is likely to vary between individuals and cannot be determined from the available data.

Lipid peroxidation processes in men with type 1 diabetes mellitus following α-lipoic acid treatment

<abstract> <p>In various pathological conditions such as diabetes mellitus, the cellular redox balance can be disturbed and these alterations may persist even after blood glucose levels have returned to normal. Antioxidant therapies, including α-lipoic acid, are widely used to treat various systemic diseases including diabetes mellitus. The aim of this study was to measure the lipid metabolism parameters, as well as the activity of lipid peroxidation and antioxidant defense reactions, in men with type 1 diabetes mellitus (T1DM) during treatment with α-lipoic acid. Twenty-four reproductive-age T1DM males with an unsatisfactory glycemic profile were examined. Twenty-eight practically healthy men of similar age were used as the control group. Spectrophotometric, fluorometric, and enzyme-linked immunoassay methods were used. T1DM was characterized by increased values of lipid metabolism components, including total cholesterol, triacylglycerides (TG), and very-low-density lipoproteins (VLDL). In the lipid peroxidation system, increased levels of the primary products (conjugated dienes), secondary products (thiobarbituric acid reactants), and final products (Schiff bases) were observed in T1DM patients compared to the control group. Retinol values were also increased. After treatment, there was a decrease in TG, VLDL, and Schiff bases levels and an increase in the retinol level compared to before treatment. These results expand our understanding of the pathogenetic mechanisms of T1DM and suggest that α-LA treatment may be beneficial for type 1 diabetics.</p> </abstract>

A Simplified Method for Simultaneous Determination of α-Lipoic Acid and Low-Molecular-Mass Thiols in Human Plasma

α-Lipoic acid, glutathione, cysteine, and cysteinylglycine can be applied as therapeutic agents in civilization diseases such as diabetes mellitus, cardiovascular diseases, and cancers. On the other hand, a higher concentration of homocysteine can result in health problems and has been indicated as an independent risk factor for cardiovascular disease and accelerated atherosclerosis. Here, the first simplified HPLC-UV assay that enables simultaneous determination of α-lipoic acid and low-molecular-mass thiols in plasma, reduces the number of steps, shortens the total time of sample preparation, and limits the amount of single-use polypropylene laboratory materials is described. The assay is based on reversed-phase high performance liquid chromatography with UV detection and simultaneous reduction of disulfide bound with tris(2-carboxyethyl)phosphine and the selective pre-column derivatization of the thiol group with 1-benzyl-2-chloropyridinium bromide. Linearity in the detector responses for plasma samples were observed in ranges: 0.12-5.0 nmol mL^-1 for α-lipoic acid; 2.0-20.0 nmol mL^-1 for glutathione, cysteinylglycine, and homocysteine; and 40.0-400.0 for cysteine. The LODs for α-lipoic acid and low-molecular-mass thiols were 0.08 and 0.12 nmol mL^-1, respectively, while LOQs were 0.12 and 0.16 nmol mL^-1, respectively. The usefulness of the proposed method has been proven by its application to real samples.

Investigation of lipoic acid - 4-methoxybenzyl alcohol reaction and evaluation of its analytical usefulness

The presented work is aimed to synthesize a new UV active derivative of α-lipoic acid (ALA) by its esterification with 4-methoxybenzyl alcohol (4-MBA, anise alcohol). The formation of ester was confirmed by ¹HNMR, FTIR and UV spectroscopy. The analytical usefulness of the obtained compound for quantification of ALA in food items was examined using HPLC-UV and GC-MS systems. It was found that it is possible to assay ALA in the ester form in the concentration ranges: 5·10^-6-1·10^-4 mol L^-1 by HPLC-UV and 1∙10^-7-5∙10^-5 mol L^-1 by GC-MS techniques. The GC-MS procedure was applied for the determination of ALA in the food samples.

Quantification of Alpha Lipoic Acid in Pharmaceutical Products by HPLC with Pulsed Amperometric Detection at a Gold Electrode

Background:

Alpha-lipoic acid (ALA) has become a common ingredient in food supplements and multivitamin formulas. ALA is widely used as therapy for preventing diabetic polyneuropathies, scavenges free radicals, and restores intracellular glutathione levels. This study aimed to develop a simple and fast analytical method to determine ALA content in dietary supplements using highperformance liquid chromatography with pulsed amperometric detection (HPLC PAD).

Methods:

ALA was analyzed by HPLC in a mobile phase composed of 25 mmol/L potassium phosphate in 50% (v/v) acetonitrile (pH 4.0) and PAD at a gold electrode (vs. solid-phase hydrogen reference electrode). The PAD cycle was performed by applying a detection potential (E1) of +0.7 V for 0.4 s, an oxidation potential (E2) of +1.0V for 0.4 s and a reduction potential (E3) of -0.2 V for 1.2 s.

Results:

The runtime method was shown a rapid procedure for the analysis of α-lipoic acid. The sampling rate of 8 injections per hour was attained and measurements of the reproducibility of successive injections (20 µL) showed an RSD of 1.89% for 16 successive injections. The method presented low quantification limit of 0.21 mg/L. The industrialized ALA-based supplements ranged from to 97.8 to 104.1%, while manipulated capsules ranged from 69.2 to 95.4%.

Conclusion:

Electrochemical detector has been presented as an effective alternative for ALA determination, which has weakly UV-absorbing. This detection has the benefits of sensitivity, simplicity and low costs. The developed HPLC-DAD method proposes to be analytical tool applicable to quality control of ALA supplements.

The Effect of 600 mg Alpha-lipoic Acid Supplementation on Oxidative Stress, Inflammation, and RAGE in Older Adults with Type 2 Diabetes Mellitus

Alpha-lipoic acid (ALA) has been used as a dietary supplement at different doses in patients with diabetes mellitus type 2 (T2DM) due to its antioxidant, anti-inflammatory, and hypoglycemic effects. However, the reports on the effects of ALA are controversial. For this reason, the purpose of the present study was to determine the effect of 600 mg/day of ALA on the markers of oxidative stress (OxS) and inflammation and RAGE in older adults with T2DM. A quasiexperimental study was carried out with a sample of 135 sedentary subjects (98 women and 37 men) with a mean age of 64 ± 1 years, who all had T2DM. The sample was divided into three groups: (i) experimental group (EG) with 50 subjects, (ii) placebo group (PG) with 50 subjects, and control group (CG) with 35 subjects. We obtained the following measurements in all subjects (pre- and posttreatment): glycosylated hemoglobin (HbA1c), receptor for advanced glycation end products (RAGE), 8-isoprostane, superoxide dismutase (SOD), glutathione peroxidase (GPx), total antioxidant status (TAS), and inflammatory (CRP, TNF-α, IL-6, IL-8, and IL-10) markers. Regarding the effect of ALA on HbA1c, a decrease was observed in the EG (baseline 8.9 ± 0.2 vs. posttreatment 8.6 ± 0.3) and the PG (baseline 8.8 ± 0.2 vs. posttreatment 8.4 ± 0.3) compared to the CG (baseline 8.8 ± 0.3 vs. six months 9.1 ± 0.3) although the difference was not statistically significant (p < 0.05). There was a statistically significant decrease (p < 0.05) in the blood concentration of 8-isoprostane in the EG and PG with respect to the CG (EG: baseline 100 ± 3 vs. posttreatment 57 ± 3, PG: baseline 106 ± 7 vs. posttreatment 77 ± 5, and CG: baseline 94 ± 10 vs. six months 107 ± 11 pg/mL). Likewise, a statistically significant decrease (p < 0.05) in the concentration of the RAGE was found in the EG (baseline 1636 ± 88 vs. posttreatment 1144 ± 68) and the PG (baseline 1506 ± 97 vs. posttreatment 1016 ± 82) compared to CG (baseline 1407 ± 112 vs. six months 1506 ± 128). A statistically significant decrease was also observed in all markers of inflammation and in the activity of SOD and GPx in the CG with respect to the EG and PG. Our findings suggest that the administration of ALA at a dose of 600 mg/day for six months has a similar effect to that of placebo on oxidative stress, inflammation, and RAGE in older adults with T2DM. Therefore, higher doses of ALA should be tried to have this effect. This trial is registered with trial registration number ISRCTN13159380.

The issue of HPLC determination of endogenous lipoic acid in human plasma

Lipoic acid (LA) is used extensively as a therapeutic agent for the treatment of various diseases. Many methods have been reported for the determination of LA plasma levels and its metabolites after its supplementation, but available information concerning endogenous plasma levels is still scarce. Studies which directly focused on determining the endogenous plasma levels provided highly controversial results, <4.9 nmol/L or 143.7-197.0 nmol/L. The main aim of this study was to verify the levels of free LA in the plasma of 40 individuals (17 women, 23 men). This group was nonsupplemented with LA and met the conditions for incorporation into the blood donors register. We measured the levels of LA using an HPLC method with very sensitive coulometric detection after previous sample preparation including deproteination and solid-phase extraction with a Phenyl cartridge. Our limit of detection was 1.85 nmol/L and was better than the values reported in studies that directly focused on determining the endogenous plasma levels of LA: 2.4 and 4.9 nmol/L respectively. However, the levels of free LA in the plasma of nonsupplemented voluntary blood donors were not detectable in all cases. The presented results of our study show that endogenous concentrations of LA are <1.85 nmol/L.

Determination of lipoic acid in biological samples

α-Lipoic acid (LA) is a unique antioxidant that is not only effective in affording protection against oxidative stress but also plays an essential role in metabolic processes of all living organisms. Therefore, the determination of LA and its metabolites content is crucial for understanding their physiological and pathophysiological functions. Most of the recently developed methods for the detection and determination of LA and its metabolites in various biological samples have focused on sample preparation procedures involving but not limited to sampling, extraction and storage. The main goal of this review is to summarize and critically evaluate the current state of the art of analytical procedures applied to the determination of LA and related compounds in biological samples.

Lipoic acid plays a role in scleroderma: insights obtained from scleroderma dermal fibroblasts

Introduction

Systemic sclerosis (SSc) is a connective tissue disease characterized by fibrosis of the skin and organs. Increase in oxidative stress and platelet-derived growth factor receptor (PDGFR) activation promote type I collagen (Col I) production, leading to fibrosis in SSc. Lipoic acid (LA) and its active metabolite dihydrolipoic acid (DHLA) are naturally occurring thiols that act as cofactors and antioxidants and are produced by lipoic acid synthetase (LIAS). Our goals in this study were to examine whether LA and LIAS were deficient in SSc patients and to determine the effect of DHLA on the phenotype of SSc dermal fibroblasts. N-acetylcysteine (NAC), a commonly used thiol antioxidant, was included as a comparison.

Methods

Dermal fibroblasts were isolated from healthy subjects and patients with diffuse cutaneous SSc. Matrix metalloproteinase (MMPs), tissue inhibitors of MMPs (TIMP), plasminogen activator inhibitor 1 (PAI-1) and LIAS were measured by enzyme-linked immunosorbent assay. The expression of Col I was measured by immunofluorescence, hydroxyproline assay and quantitative PCR. PDGFR phosphorylation and α-smooth muscle actin (αSMA) were measured by Western blotting. Student’s t-tests were performed for statistical analysis, and P-values less than 0.05 with two-tailed analysis were considered statistically significant.

Results

The expression of LA and LIAS in SSc dermal fibroblasts was lower than normal fibroblasts; however, LIAS was significantly higher in SSc plasma and appeared to be released from monocytes. DHLA lowered cellular oxidative stress and decreased PDGFR phosphorylation, Col I, PAI-1 and αSMA expression in SSc dermal fibroblasts. It also restored the activities of phosphatases that inactivated the PDGFR. SSc fibroblasts produced lower levels of MMP-1 and MMP-3, and DHLA increased them. In contrast, TIMP-1 levels were higher in SSc, but DHLA had a minimal effect. Both DHLA and NAC increased MMP-1 activity when SSc cells were stimulated with PDGF. In general, DHLA showed better efficacy than NAC in most cases.

Conclusions

DHLA acts not only as an antioxidant but also as an antifibrotic because it has the ability to reverse the profibrotic phenotype of SSc dermal fibroblasts. Our study suggests that thiol antioxidants, including NAC, LA, or DHLA, could be beneficial for patients with SSc.

Electronic supplementary material

The online version of this article (doi:10.1186/s13075-014-0411-6) contains supplementary material, which is available to authorized users.